Print

Print


Told ya it eliminated my ocular migraines and my CG at the time of surgeries
claimed I was calmer:

How Will Deep Brain Stimulation Affect Neurological and Psychiatric Drug
Markets?
Decision Resources, Inc., Aug 2006, Pages: 26

Deep brain stimulation (DBS) is currently approved only to treat Parkinsons
disease and Parkinson-like symptoms; however, clinical trials are under way
for DBS in several other neurological and psychiatric disorders. As these
surgical interventions gain acceptance in the face of conventional therapies
shortcomings in severely affected patients, opportunities are emerging for
such devices, used both alone and in conjunction with existing drug
regimens.

Get the Answers You Need to Shape Your Strategy
Currently, DBS is approved only for Parkinsonism. For what other indications
is DBS being investigated? What advantages does DBS offer to treat these
indications? What potential exists for DBS in these indications?
The risk factors associated with DBS have made it a last-resort therapy for
most indications.
How competitive will DBS be with conventional drug therapies? In which
indications will it stand out? Will DBS ever be used as an early therapy, in
any indication?
Medtronic is the only company to have an approved device for DBS, although
several companies have devices in development for other indications. Which
of the companies developing DBS devices is best positioned to succeed in
these new markets? What innovations must these companies provide to ensure
success? Which company is poised to collaborate with drug makers in creating
a viable combination therapy?

Scope of this Report:

- Therapeutic overview: medical and regulatory landscape for DBS.
- Indications covered: Parkinsons disease, epilepsy, obsessive-compulsive
disorder, depression, and headaches including migraines.
- Companies developing DBS devices: profi les of companies developing
devices for the DBS market.
- Drug markets: impact of DBS therapy on indication-specifi c drug markets.
- Market outlook: considerations for the DBS device market over 2005-2015
including cost and patient share and physician opinion.

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn